title: Innate immune evasion of Escherichia coli clinical strains from orthopedic implant infections.
abstract: Escherichia coli is one of the first causes of Gram-negative orthopedic implant infections (OII). Those infections, usually hematogenous, mostly originate from the urinary tract. We investigated the strategies developed by E. coli in this context to evade host innate immune responses, i.e. complement and polymorphonuclear neutrophils (PMN). Twenty strains from OII were compared with 20 strains from bacteremia in patients with non-infected orthopedic implant. In both groups, 6/20 (30 %) strains lysed PMNs, due to the production of the pore-forming toxin α-hemolysin (HlyA). For the others, resistance to phagocytic killing by PMN was not significantly different between both groups. In contrast, resistance to complement-mediated serum killing was significantly higher in OII strains than in the others (65 % vs 10 %; P <0.001). In E. coli, different mechanisms have been involved in complement resistance. Here, serum resistance was not linked to a group 2 capsule, or a loss of outer membrane permeability, or the recruitment of the complement inhibitor C4bp, but was significantly associated with the synthesis of long-chain LPS, regardless of the O-antigen. Thus, serum resistance could promote seeding of peri-implant tissues by helping E. coli to either persist in blood and reach the site of infection or overcome localized complement activation.
authors.affiliation: UFR de Médecine, EA3826, Thérapeutiques cliniques et expérimentales des infections, Université de Nantes, 1 rue G. Veil, 44000, Nantes, France.|Pôle de Biologie, Service de Bactériologie-Hygiène, CHU de Nantes, France.
authors.forename: L
authors.initials: L
authors.lastname: Crémet
authors.affiliation: UFR de Médecine, EA3826, Thérapeutiques cliniques et expérimentales des infections, Université de Nantes, 1 rue G. Veil, 44000, Nantes, France.
authors.forename: A
authors.initials: A
authors.lastname: Broquet
authors.affiliation: UFR de Médecine, EA3826, Thérapeutiques cliniques et expérimentales des infections, Université de Nantes, 1 rue G. Veil, 44000, Nantes, France.
authors.forename: C
authors.initials: C
authors.lastname: Jacqueline
authors.affiliation: UFR de Médecine, EA3826, Thérapeutiques cliniques et expérimentales des infections, Université de Nantes, 1 rue G. Veil, 44000, Nantes, France.
authors.forename: C
authors.initials: C
authors.lastname: Chaillou
authors.affiliation: UFR de Médecine, EA3826, Thérapeutiques cliniques et expérimentales des infections, Université de Nantes, 1 rue G. Veil, 44000, Nantes, France.|Pôle Anesthésie Réanimation, Service d'Anesthésie Réanimation Chirurgicale, CHU de Nantes, France.
authors.forename: K
authors.initials: K
authors.lastname: Asehnoune
authors.affiliation: UFR de Médecine, EA3826, Thérapeutiques cliniques et expérimentales des infections, Université de Nantes, 1 rue G. Veil, 44000, Nantes, France.|Pôle de Biologie, Service de Bactériologie-Hygiène, CHU de Nantes, France.
authors.forename: S
authors.initials: S
authors.lastname: Corvec
authors.affiliation: UFR de Médecine, EA3826, Thérapeutiques cliniques et expérimentales des infections, Université de Nantes, 1 rue G. Veil, 44000, Nantes, France. nathalie.caroff@univ-nantes.fr.
authors.forename: N
authors.initials: N
authors.lastname: Caroff
mesh_terms: D016470:Bacteremia; D002470:Cell Survival; D004926:Escherichia coli / Q000145:classification / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity*; D004927:Escherichia coli Infections / Q000276:immunology* / Q000382:microbiology*; D006801:Humans; D057131:Immune Evasion; D007113:Immunity, Innate; D058885:Multilocus Sequence Typing; D009504:Neutrophils / Q000276:immunology / Q000382:microbiology; D010802:Phylogeny; D016459:Prosthesis-Related Infections; D065288:Serogroup